{"contentid": 488229, "importid": NaN, "name": "Ophthalmic bevacizumab takes aim at anti-VEGF market", "introduction": "An ophthalmic  formulation of Roche and Genentech\u00e2\u0080\u0099s Avastin (bevacizumab), under development for use in retinal indications, has fared well in a Phase III safety study.", "content": "<p>An ophthalmic formualtion of Roche (ROG: SIX) and Genentech&rsquo;s Avastin (bevacizumab), under development for use in retinal indications, has fared well in a Phase III safety study.</p>\n<p>Spying an opportunity to offer an ophthalmic formulation of the anti-VEGF biologic, Outlook Therapeutics (Nasdaq: OTLK) is testing bevacizumab-vikg in the NORSE THREE open-label study.</p>\n<p>Top-line results showed no unexpected safety trends, indicating a safety profile consistent with that of prior published data on the use of bevacizumab for ophthalmic conditions.</p>\n<p>In a statement, the firm said: &ldquo;Notably, there were zero cases of ocular inflammation, a concern that has emerged for other anti-VEGF therapies to treat retinal conditions.&rdquo;</p>\n<h2>Targeting eye disease</h2>\n<p>With no FDA-approved ophthalmic formulation of bevacizumab available, Outlook argues it can offer a safer and more reliable option than the use of repackaged intravenous (IV) Avastin, a product offered by compounding pharmacists in the USA.</p>\n<p>This would enable doctors to provide a less expensive anti-VEGF drug than Lucentis (ranibizumab), Eylea (aflibercept) or Beovu (brolucizumab-dbll), without compromising on quality or safety.</p>\n<p>If approved, Outlook plans to market the treatment as Lytenava.</p>\n<p>The firm recently raised $35 million through a common stock offering, providing the necessary capital to advance the candidate through a US regulatory submission in wet AMD.</p>\n<p>Chief executive Lawrence Kenyon said the money would also enable the firm to &ldquo;continue discussions with potential partners as we evaluate the best path forward to commercialize&rdquo; the product.</p>\n<p>The candidate's safety and efficacy are being evaluated in the ongoig pivitol NORSE TWO trial, and the firm is gearing up for a regulatory submission in the fourth quarter of 2021.</p>\n<p>Commenting on the latest trial data, Mr Kenyon said: &ldquo;These results reinforce the positive safety profile seen in our earlier clinical experience trial.&rdquo;</p>\n<p>He added: &ldquo;Moving forward, our team is now laser-focused on successfully completing our pivotal trial, NORSE TWO, and preparing the BLA after the data readout expected in the third quarter of this calendar year.&rdquo;</p>", "date": "2021-04-01 11:37:00", "meta_title": NaN, "meta_keywords": "safety, bevacizumab, anti-VEGF, biosimilar, retinal, study, Avastin, firm, takes, ophthalmic, data, market, fared, Roche, indications, development, Phase", "meta_description": "A biosimilar of Roche and Genentech\u00e2\u0080\u0099s Avastin (bevacizumab), under development for use in retinal indications, has fared well in a Phase III safety study.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 11:21:18", "updated": "2021-04-02 15:59:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/biosimilar-bevacizumab-takes-aim-at-anti-vegf-market", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "oulook_big.jpg", "image2id": "outlook_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars", "therapy area_tag": "Ophthalmics", "topic_tag": "Drug Trial, Regulation, Research", "geography_tag": "USA", "company_tag": "Outlook Therapeutics", "drug_tag": "Lytenava", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 11:37:00"}